BioCryst begins Phase 1 trial of BCX17725 (KLK5 inhibitor) for Netherton syndrome

BIOCRYST PHARMACEUTICALS INC

First participant enrolled in Phase 1 trial of BCX17725, a KLK5 inhibitor for Netherton syndrome.
Trial to evaluate safety, tolerability, PK and immunogenicity in healthy adults and Netherton patients.
Initial data from the trial expected by end of 2025; no approved treatments currently exist for the disease.
BCX17725 is BioCryst's first protein therapeutic to advance to the clinic.
Netherton syndrome is an ultra-rare, life-threatening genetic disorder affecting skin, hair, and immune system.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.